Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
Stopped early · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estradiol may kill prostate cancer cells that no longer respond to hormone therapy. Giving paclitaxel poliglumex together with estradiol may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel poliglumex together with estradiol works in treating patients with stage IV prostate cancer.
Key facts
- Study ID
- NCT00459810
- Run by
- OHSU Knight Cancer Institute
- People needed
- 21
- Starts
- 2007-02-01
- Expected to finish
- 2009-07-01
- Last updated by the study team
- 2017-04-28
Who can join
Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.
Where it is running
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
- OHSU Knight Cancer Institute — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.